Abeona Therapeutics (ABEO) to Release Quarterly Earnings on Wednesday

Abeona Therapeutics (NASDAQ:ABEO) is anticipated to post its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect Abeona Therapeutics to post earnings of ($0.33) per share and revenue of $4.5720 million for the quarter. Interested persons may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 8:30 AM ET.

Abeona Therapeutics (NASDAQ:ABEO) last posted its earnings results on Tuesday, March 17th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.01. The business had revenue of $3.00 million for the quarter, compared to analyst estimates of $5.65 million. On average, analysts expect Abeona Therapeutics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Abeona Therapeutics Price Performance

Shares of NASDAQ ABEO opened at $5.90 on Monday. The stock has a fifty day moving average price of $5.02 and a 200 day moving average price of $5.03. The company has a current ratio of 6.93, a quick ratio of 6.74 and a debt-to-equity ratio of 0.05. Abeona Therapeutics has a 12-month low of $4.00 and a 12-month high of $7.54. The company has a market cap of $335.59 million, a P/E ratio of 5.73 and a beta of 1.35.

Institutional Trading of Abeona Therapeutics

A number of hedge funds have recently made changes to their positions in ABEO. Deutsche Bank AG raised its holdings in Abeona Therapeutics by 6.2% in the fourth quarter. Deutsche Bank AG now owns 39,368 shares of the biopharmaceutical company’s stock valued at $207,000 after acquiring an additional 2,303 shares in the last quarter. LPL Financial LLC raised its stake in shares of Abeona Therapeutics by 5.3% in the 4th quarter. LPL Financial LLC now owns 62,873 shares of the biopharmaceutical company’s stock valued at $331,000 after purchasing an additional 3,165 shares in the last quarter. Intech Investment Management LLC lifted its position in shares of Abeona Therapeutics by 19.6% during the third quarter. Intech Investment Management LLC now owns 25,176 shares of the biopharmaceutical company’s stock worth $133,000 after purchasing an additional 4,127 shares during the last quarter. Creative Planning lifted its position in shares of Abeona Therapeutics by 43.0% during the second quarter. Creative Planning now owns 14,310 shares of the biopharmaceutical company’s stock worth $81,000 after purchasing an additional 4,305 shares during the last quarter. Finally, Legal & General Group Plc acquired a new position in Abeona Therapeutics in the second quarter worth about $27,000. Institutional investors and hedge funds own 80.56% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the company. Weiss Ratings reiterated a “sell (d+)” rating on shares of Abeona Therapeutics in a research note on Wednesday, January 21st. Stifel Nicolaus set a $17.00 price target on Abeona Therapeutics in a report on Tuesday, March 17th. HC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of Abeona Therapeutics in a research note on Thursday, March 19th. Finally, Oppenheimer reissued an “outperform” rating on shares of Abeona Therapeutics in a research report on Monday, March 9th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Abeona Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $19.00.

Abeona Therapeutics Company Profile

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.